Want to see IN:AKUMS full AI Analyst Report?
AKUMS Stock Chart & Stats
₹684.40
-₹11.70(-1.70%)
At close: 4:00 PM EDT
₹684.40
-₹11.70(-1.70%)
Day’s Range― - ―
52-Week Range₹410.10 - ₹839.25
Previous CloseN/A
Volume178.53K
Average Volume (3M)9.39K
Market Cap
₹105.15B
Enterprise Value₹56.30B
Total Cash (Recent Filing)₹16.78B
Total Debt (Recent Filing)₹902.87M
Price to Earnings (P/E)35.1
Beta1.22
Next Earnings
Nov 09, 2026EPS Estimate
6.35Next Dividend Ex-DateN/A
Dividend Yield0.45%
Share Statistics
EPS (TTM)12.42
Shares Outstanding157,393,980
10 Day Avg. Volume7,925
30 Day Avg. Volume9,389
Financial Highlights & Ratios
PEG Ratio-1.07
Price to Book (P/B)2.15
Price to Sales (P/S)1.64
P/FCF Ratio7.28
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)27.23
Revenue Forecast (FY)₹50.25B
Bulls Say, Bears Say
Bulls Say
Revenue Growth And Profit TurnaroundThe combination of multi-year revenue expansion and a return to positive earnings indicates improving commercial scale and business resilience. If sustained, higher volumes and broader customer demand can support stronger operating leverage and provide a foundation for continued reinvestment.
Conservative Balance SheetThe sharp reduction in leverage materially strengthens financial flexibility and reduces the burden of debt service. A stronger capital base gives Akums greater capacity to fund capacity, development, or working-capital needs while improving its ability to withstand periods of weaker profitability.
Improved Cash GenerationStrong recent operating and free cash flow provides tangible support for earnings quality and internal funding. Cash generation can help the company finance growth, maintain its strengthened balance sheet, and reduce reliance on external capital if the improved conversion persists.
Bears Say
Sharp Margin CompressionThe substantial FY26 margin decline shows that revenue growth is not translating consistently into profit. Persistent pressure from cost, product mix, or other operating factors could reduce earnings durability, weaken returns on the expanded capital base, and limit reinvestment capacity.
Volatile Cash ConversionAlthough recent cash generation is strong, the historical pattern demonstrates that accounting earnings have not always converted reliably into cash. Continued volatility could complicate investment planning, increase dependence on working-capital management, and make internally funded expansion less predictable.
Recent Earnings SoftnessNegative EPS growth and easing returns indicate that the latest improvement in financial strength has not fully translated into expanding per-share profitability. If earnings remain under pressure, shareholder returns may lag revenue growth and management may have less flexibility to compound value.
Akums Drugs and Pharmaceuticals Limited News
AKUMS FAQ
What was Akums Drugs and Pharmaceuticals Limited’s price range in the past 12 months?
Akums Drugs and Pharmaceuticals Limited lowest stock price was ₹410.10 and its highest was ₹839.25 in the past 12 months.
What is Akums Drugs and Pharmaceuticals Limited’s market cap?
Akums Drugs and Pharmaceuticals Limited’s market cap is ₹105.15B.
When is Akums Drugs and Pharmaceuticals Limited’s upcoming earnings report date?
Akums Drugs and Pharmaceuticals Limited’s upcoming earnings report date is Nov 09, 2026 which is in 15 days.
How were Akums Drugs and Pharmaceuticals Limited’s earnings last quarter?
Akums Drugs and Pharmaceuticals Limited released its earnings results on Aug 08, 2026. The company reported ₹6.45 earnings per share for the quarter, beating the consensus estimate of ₹6.1 by ₹0.35.
Is Akums Drugs and Pharmaceuticals Limited overvalued?
According to Wall Street analysts Akums Drugs and Pharmaceuticals Limited’s price is currently Overvalued.
Does Akums Drugs and Pharmaceuticals Limited pay dividends?
Akums Drugs and Pharmaceuticals Limited pays a Notavailable dividend of ₹3 which represents an annual dividend yield of 0.45%. See more information on Akums Drugs and Pharmaceuticals Limited dividends here
What is Akums Drugs and Pharmaceuticals Limited’s EPS estimate?
Akums Drugs and Pharmaceuticals Limited’s EPS estimate is 6.35.
How many shares outstanding does Akums Drugs and Pharmaceuticals Limited have?
Akums Drugs and Pharmaceuticals Limited has 157,393,980 shares outstanding.
What happened to Akums Drugs and Pharmaceuticals Limited’s price movement after its last earnings report?
Akums Drugs and Pharmaceuticals Limited reported an EPS of ₹6.45 in its last earnings report, beating expectations of ₹6.1. Following the earnings report the stock price went down -2.69%.
Which hedge fund is a major shareholder of Akums Drugs and Pharmaceuticals Limited?
Currently, no hedge funds are holding shares in IN:AKUMS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Akums Drugs and Pharmaceuticals Limited
Akums Drugs & Pharmaceuticals Ltd. is an Indian-based company, established in 2004 and headquartered in Delhi, that operates globally as a manufacturer and supplier of both finished pharmaceutical products and active pharmaceutical ingredients (APIs). Its diverse product range encompasses conventional drugs, traditional Ayurvedic and herbal remedies, personal care items including toiletries, nutraceuticals, food and dietary supplements, dermatological and cosmetic products, and healthcare and hospital supplies, along with over-the-counter (OTC) solutions. The company also deals in excipients and various chemical compounds. Akums develops and markets its own branded formulations across a variety of dosage forms, such as tablets, capsules, injectables, ophthalmic preparations, and soft gelatin capsules. These products address a broad spectrum of therapeutic areas, including gynaecology, cardiology, orthopaedics, pediatrics, dermatology, anti-infectives, pain management, and gastroenterology. Furthermore, Akums Drugs & Pharmaceuticals provides services as a pharmaceutical contract development and manufacturing organization (CDMO).
Technical Analysis
Glenmark Life Sciences Limited
―
Jubilant Pharmova Limited
―
Shilpa Medicare Limited
―
Strides Pharma Science Ltd
―
Sudeep Pharma Limited
―